Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
08:41am, Wednesday, 17'th Apr 2024
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
04:06pm, Tuesday, 16'th Apr 2024
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercializatio
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
01:17pm, Tuesday, 16'th Apr 2024
Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achiev
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
08:30am, Tuesday, 19'th Mar 2024
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies Is On Fire
07:11pm, Monday, 11'th Mar 2024
Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major D
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
08:00am, Wednesday, 06'th Mar 2024
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
08:00am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
09:46am, Friday, 23'rd Feb 2024
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
10:08pm, Wednesday, 21'st Feb 2024
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
10:51pm, Saturday, 10'th Feb 2024
Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significan
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 02'nd Jan 2024
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy?
01:32pm, Tuesday, 19'th Dec 2023
Does Intra-Cellular Therapies (ITCI) have what it takes to be a top stock pick for momentum investors? Let's find out.
